CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shows promise in fighting advanced stomach cancer
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) helps people with advanced stomach or esophageal cancer live longer without their disease getting worse. About 224 adults whose cancer has a specific marker (PD-…
Matched conditions: CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
Radiation-Activated nanoparticle shows promise in early esophageal cancer trial
Disease control Recruiting nowThis early-phase study tests a new drug called NBTXR3, which is injected into the tumor and activated by radiation therapy, alongside standard chemotherapy. The goal is to find the safest dose and see if it helps control esophageal cancer. About 24 adults with stage II or III eso…
Matched conditions: CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
Could a common heart drug boost cancer treatment?
Disease control Recruiting nowThis study tests whether adding propranolol (a beta-blocker used for heart conditions) to standard chemotherapy and immunotherapy can help shrink tumors in people with advanced esophageal or gastroesophageal junction cancer that cannot be surgically removed. The trial enrolls 40 …
Matched conditions: CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 15, 2026 19:04 UTC
-
New radiation approach may spare heart and lungs in esophageal cancer patients
Disease control Recruiting nowThis study compares two radiation methods for people with stage I to IVA esophageal cancer: proton beam therapy and standard photon radiation (IMRT). The goal is to see which one helps patients live longer and causes fewer serious heart and lung side effects. About 300 adults wil…
Matched conditions: CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New combo before surgery aims to boost esophageal cancer outcomes
Disease control Recruiting nowThis study is for people with stage I to III esophageal or gastroesophageal junction cancer who are scheduled for surgery. It tests whether giving a shorter, higher-dose course of radiation along with the chemotherapy drugs FOLFOX before surgery can kill more tumor cells and caus…
Matched conditions: CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New chemo combo tested to extend life in Hard-to-Treat stomach and esophageal cancers
Disease control Recruiting nowThis study tests whether a stronger chemotherapy mix (mFOLFIRINOX) works better than the standard mix (FOLFOX) for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. Some participants also receive the immunotherapy dru…
Matched conditions: CLINICAL STAGE III ESOPHAGEAL ADENOCARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC